Randall Colin Gouveia
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
NL Upgraded to Outperform on CompX Strength, Kronos Recovery. The rating upgrade reflects a more positive outlook after CompX's strong performance and Kronos's recovery. NL is near its 52‑week low but sits above the $5.65 support level, and the RSI of 59.5 indicates a moderate trend.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Kronos Worldwide Shares Up 72% Year-to-Date. Kronos Worldwide stock has risen 72% since the start of the year, outperforming many peers in the basic materials sector. This significant gain places the stock near the upper end of its 52-week range, despite a current RSI of 35.4 suggesting recent cooling in momentum. The company also offers a high dividend yield of 8.93%.
Transaction History
| ROG | ▼ Sell | Tax Withholding | 1,996 | $179K | 2/19/2025 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 459 | $41K | 2/14/2025 | View on chart |
| ROG | ▲ Buy | Grant | 19,826 | $0 | 2/12/2025 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 1,713 | $151K | 2/9/2025 | View on chart |
| ROG | ▲ Buy | Grant | 13,970 | $0 | 2/19/2024 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 298 | $35K | 2/14/2024 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 231 | $28K | 2/10/2024 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 1,115 | $133K | 2/9/2024 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 309 | $46K | 2/14/2023 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 224 | $34K | 2/12/2023 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 238 | $36K | 2/10/2023 | View on chart |
| ROG | ▲ Buy | Grant | 603 | $0 | 2/9/2023 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 198 | $30K | 2/9/2023 | View on chart |
| ROG | ▲ Buy | Grant | 11,640 | $0 | 2/9/2023 | View on chart |
| ROG | ▼ Sell | Open Market | 1,502 | $400K | 8/19/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 210 | $56K | 6/3/2022 | View on chart |
| NL | ▲ Buy | Grant | 2,500 | — | 5/19/2022 | View on chart |
| KRO | ▲ Buy | Grant | 1,200 | — | 5/18/2022 | View on chart |
| ROG | ▲ Buy | Grant | 3,210 | $0 | 2/14/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 265 | $72K | 2/12/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 236 | $64K | 2/10/2022 | View on chart |
| ROG | ▲ Buy | Grant | 2,367 | $0 | 2/9/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 691 | $189K | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Roche presents new Phase III data and FDA approval
Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.
Roche presents new Phase III data and FDA approval. Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.